Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses. [Read More]
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large. [Read More]
Sponsored by Our Lab is Everywhere
Can today's research drive tomorrow's treatment?
In the pursuit of knowledge, see how we uncover unknowns in moderate to severe RA and PsA.USA-916-82440SEE OUR FINDINGS